Amour Venter - Concepedia

Author

Amour Venter

Also Known As

A Venter, A. VENTER, A. Venter, A.C. Venter, ADRIAN NICOLAE VENTER, Adrian Nicolae Venter, Amour Venter, Annette Venter, Robert Wallis, Roger Vargas Jr

Publications

Citations

H-Index

Concepts

All Affiliations

Stellenbosch University University of Cape Town Task Applied Science South African Medical Research Council Karl Bremer Hospital

About

Amour Venter is an author at Stellenbosch University specializing in medicine, antimicrobial resistance, and clinical microbiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	16	1.7K
2	Health Sciences	7	7	702
3	Natural Sciences	2	2	32
4	Biology	2	2	32
5	Engineering	1	1	16

Amour Venter

Publications

4.8K

Citations

H-Index

Page 1

	Year	Citations
The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis Andreas H. Diacon, Alexander S. Pym, Martin P. Grobusch, New England Journal of Medicine	2009	836
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial Andreas H. Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, The Lancet AntibioticsMedicineRandomised Trial14-Day Bactericidal ActivityAntibacterial Agent	2012	428
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial Martin J. Boeree, Norbert Heinrich, Rob E. Aarnoutse, The Lancet Infectious Diseases	2016	379
A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis Martin J. Boeree, Andreas H. Diacon, Rodney Dawson, American Journal of Respiratory and Critical Care Medicine	2015	310
Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis Roxana Rustomjee, Andreas H. Diacon, Jenny Allen, Antimicrobial Agents and Chemotherapy	2008	276
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt, The Lancet Pulmonary TuberculosisPhase 2BTuberculosis PreventionPharmacologyTuberculosis	2015	248
Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients Andreas H. Diacon, Rodney Dawson, M. Hanekom, The International Journal of Tuberculosis and Lung Disease	2011	203
Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline Andreas H. Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, American Journal of Respiratory and Critical Care Medicine	2015	200
Early Bactericidal Activity of High-Dose Rifampin in Patients with Pulmonary Tuberculosis Evidenced by Positive Sputum Smears Andreas H. Diacon, R. F. Patientia, Amour Venter, Antimicrobial Agents and Chemotherapy Pulmonary Tuberculosis EvidencedHigher Rifampin DosesHigh-dose RifampinPulmonary TuberculosisHealth Sciences	2007	196
Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment Sven O. Friedrich, Andrea Rachow, Elmar Saathoff, The Lancet Respiratory Medicine	2013	187

Page 1